keryx biopharmaceuticals
(KERX:NASDAQ CM)

Financial Statements for keryx biopharmaceuticals (KERX)

Currency in Millions of US Dollars	As of:	Dec 31 2009 Restated	Dec 31 2010 Restated	Dec 31 2011	Dec 31 2012	4 Year Trend
Revenues		21.6	--	5.0	--
TOTAL REVENUES		21.6	--	5.0	--
GROSS PROFIT		21.6	--	5.0	--
Selling General & Admin Expenses, Total		5.3	6.3	6.7	7.0
R&D Expenses		7.1	15.0	27.0	20.0
OTHER OPERATING EXPENSES, TOTAL		12.4	21.2	33.7	27.1
OPERATING INCOME		9.2	-21.2	-28.7	-27.1
Interest and Investment Income		0.3	0.1	0.2	0.1
NET INTEREST EXPENSE		0.3	0.1	0.2	0.1
Other Non-Operating Income (Expenses)		0.2	0.2	0.2	0.2
EBT, EXCLUDING UNUSUAL ITEMS		9.8	-20.8	-28.4	-26.9
Gain (Loss) on Sale of Investments		0.1	-0.1	--	--
Other Unusual Items, Total		0.6	0.5	--	1.5
Other Unusual Items		0.6	0.5	--	1.5
EBT, INCLUDING UNUSUAL ITEMS		10.5	-20.5	-28.4	-25.4
Earnings from Continuing Operations		10.5	-20.5	-28.4	-25.4
EARNINGS FROM DISCOUNTINUED OPERATIONS		0.0	0.1	0.2	--
Extraordinary Item & Accounting Change		--	--	--	2.6
NET INCOME		10.5	-20.3	-28.1	-22.7
NET INCOME TO COMMON INCLUDING EXTRA ITEMS		10.5	-20.3	-28.1	-22.7
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS		10.5	-20.5	-28.4	-25.4

Report Data Issue

To contact KERYX BIOPHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.